公开(公告)号：US20140322704A1

公开(公告)日：2014-10-30

申请号：US14366467

申请日：2012-12-19

申请人： The Florida State University Research Foundation, Inc.

发明人： Hengli Tang ,  Xianfang Wu

IPC分类号： C12N7/00 ,  C12Q1/02 ,  C12N5/071

CPC分类号： C12N7/00 ,  C12N5/067 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/415 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2730/10151 ,  C12N2770/24251 ,  C12Q1/025 ,  C12Q1/18 ,  G01N33/5067 ,  G01N33/5767

摘要： The invention relates to the discovery that DHH derived from stem cells are permissive for infection by hepatitis viruses (HV), such as hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). Included in the invention are HV-permissive DHHs and methods of making an HCV-permissive DHH derived from a stem cell. Also included is an HV culture system comprising at least one HV-permissive DHH. The HV-permissive DHH and HV culture system are useful for conducting HV life cycle analyses, diagnosing a subject as being infected with HV, genotyping and characterizing the HV of a subject infected with HV, detecting drug resistance of HV obtained from a subject infected with HV, screening for and identify modulators of HV infection, and monitoring the effect of a treatment of HV in a subject.

摘要翻译： 本发明涉及从干细胞衍生的DHH允许肝炎病毒（HV）如甲型肝炎病毒（HAV），乙型肝炎病毒（HBV），丙型肝炎病毒（HCV），丙型肝炎病毒（HCV） HDV）和戊型肝炎病毒（HEV）。 本发明中包括HV允许DHH和制备衍生自干细胞的HCV允许DHH的方法。 还包括HV培养系统，其包括至少一种HV允许DHH。 HV允许DHH和HV培养系统可用于进行HV生命周期分析，诊断被感染HV的受试者，对感染HV的受试者的HV进行基因分型和表征，检测从感染的受试者获得的HV的耐药性 HV，筛选和鉴定HV感染的调节剂，并监测受试者中HV的治疗效果。